Stabilisation of atherosclerotic plaques: Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Summary: Plaque rupture and subsequent thrombotic occlusion of the coronary artery account for as many as three quarters of myocardial infarctions. The concept of plaque stabilisation emerged about 20 years ago to explain the discrepancy between the reduction of cardiovascular events in patients receiving lipid lowering therapy and the small decrease seen in angiographic evaluation of atherosclerosis. Since then, the concept of a vulnerable plaque has received a lot of attention in basic and clinical research leading to a better understanding of the pathophysiology of the vulnerable plaque and acute coronary syndromes. From pathological and clinical observations, plaques that have recently ruptured have thin fibrous caps, large lipid cores, exhibit outward remodelling and invasion by vasa vasorum. Ruptured plaques are also focally inflamed and this may be a common denominator of the other pathological features. Plaques with similar characteristics, but which have not yet ruptured, are believed to be vulnerable to rupture. Experimental studies strongly support the validity of anti-inflammatory approaches to promote plaque stability. Unfortunately, reliable non-invasive methods for imaging and detection of such plaques are not yet readily available. There is a strong biological basis and supportive clinical evidence that low-density lipoprotein lowering with statins is useful for the stabilisation of vulnerable plaques. There is also some clinical evidence for the usefulness of antiplatelet agents, beta blockers and renin-angiotensin-aldosterone system inhibitors for plaque stabilisation. Determining the causes of plaque rupture and designing diagnostics and interventions to prevent them are urgent priorities for current basic and clinical research in cardiovascular area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“Subsets of mononuclear cells in the blood termed endothelial progenitor cells (EPCs) and smooth muscle progenitor cells form colonies in cell culture with endothelial or smooth muscle cell-like features, respectively (125, 126).”
Background(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 1×
“Clinical trials like HOPE and ONTARGET have shown a reduction in coronary events out of propotion to their reduction in blood pressure supporting the concept of plaque stabilising effects (199, 200).”
MethodInflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“The positive effects of prasugrel (TRITON) (194) and ticagrelor (PLATO) (195) on CVD events were even greater.”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk
Hill, J. M., Zalos, G., Halcox, J. P. J., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., & Finkel, T. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022287 · Cited by 3,423
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 3×
“By contrast, alternative activation of macrophages with IL-4 or IL-13 suppresses production of pro-inflammatory cytokines, MHC-II related antigens and proteases, and increases secretion of connective tissue growth factors, thereby promoting granuloma formation and tissue repair (52).”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(09)61717-7 · Cited by 2,546 · cited 9×
“© Schattauer 2011 Thrombosis and Haemostasis 106.1/2011 Abbreviations ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; CETP, cholesteryl ester transport protein; CRP, C-reactive protein; CVD, cardiovascular disease; eNOS, endothelial nitric oxide synthase; EPCs, endothelial progenitor cells; FCM, foam…”
BackgroundInfluentialPlump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237 · cited 1×
“The two most commonly used mouse models of atherosclerosis are the apolipoprotein E-deficient mouse (apoE-/-) (35, 36) and the LDL receptor-deficient mouse (LDLR-/-) (37).”
MethodBrown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis
Homocysteine Studies Collaboration (2002) · JAMA · doi:10.1001/jama.288.16.2015 · Cited by 2,059
Circulating endothelial progenitor cells and cardiovascular outcomes
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Böhm, M., & Nickenig, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043814 · Cited by 2,048
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044 · cited 1×
“Approximately 160 genetic loci have been identified which are associated with increased or decreased risk of diseases like coronary artery disease, MI and restenosis (169, 170).”
BackgroundEndothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace
Förstermann, U., & Münzel, T. (2006) · Circulation · doi:10.1161/circulationaha.105.602532 · Cited by 1,957 · cited 1×
“Under these circumstances, eNOS becomes no longer the source of NO but rather superoxide anions (so-called “eNOS uncoupling”) (96).”
BackgroundAdherence to Mediterranean diet and health status: meta-analysis
Sofi, F., Cesari, F., Abbate, R., Gensini, G. F., & Casini, A. (2008) · BMJ · doi:10.1136/bmj.a1344 · Cited by 1,717 · cited 1×
“5 million participants suggests that greater adherence to Mediterranean diet significantly (by 9%) reduces cardiovascular mortality (142).”
BackgroundPrognostic Value of Coronary Vascular Endothelial Dysfunction
Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M. A., Nour, K. R. A., & Quyyumi, A. A. (2002) · Circulation · doi:10.1161/01.cir.0000025404.78001.d8 · Cited by 1,385
Falk, E. (1983) · Heart · doi:10.1136/hrt.50.2.127 · Cited by 1,012 · cited 2×
“Another not uncommon source of plaque haemorrhage is extravasation of blood through a ruptured fibrous cap (19).”
BackgroundSelf-citationWatts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843 · cited 1×
“Thomas atherosclerosis regression study) randomising patients to colestyramin (183).”
BackgroundNewby, A. C. (2005) · Physiological Reviews · doi:10.1152/physrev.00048.2003 · Cited by 817
Self-citationThies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739 · cited 1×
“It applies to the role of omega-3 acids in plaque remodelling in patients awaiting the endarterectomy procedure (143).”
BackgroundVascular endothelial growth factor enhances atherosclerotic plaque progression
Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., & Dake, M. D. (2001) · Nature Medicine · doi:10.1038/86490 · Cited by 708
Macrophage plasticity in experimental atherosclerosis
Khallou-Laschet, J., Varthaman, A., Fornasa, G., Compain, C., Gaston, A.-T., Clement, M., Dussiot, M., Levillain, O., Graff-Dubois, S., Nicoletti, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008852 · Cited by 517 · cited 1×
“M2-like, MMP-12 positive FCMs occur selectively around the lipid core of rabbit and human plaques (84).”
BackgroundMacrophage Diversity and Polarization in Atherosclerosis: A Question of Balance
Mantovani, A., Garlanda, C., & Locati, M. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.180497 · Cited by 426
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246 · cited 1×
“Recently, two clinical trials indeed revealed that in statin-treated patients with low HDL-C, high-dose modified-release nicotinic acid, compared with placebo, significantly reduces carotid atherosclerosis within 12 months (202), and that the use of extended-release niacin caused a significant regression of carotid in…”
BackgroundAtherosclerotic lesions in mouse and man: is it the same disease?
Bentzon, J. F., & Falk, E. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ded6a · Cited by 147
Self-citationJain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0979 · Cited by 117 · cited 1×
“It has been suggested to use anti-angiogenic therapy for plaque stabilisation in humans (123).”
Method
Cited by
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Self-citationAnimal models of atherosclerosis
Emini Veseli, B., Perrotta, P., De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., & De Meyer, G. R. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.010 · Cited by 548
S. Antonopoulos, A., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 432
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia
Stevens, S. M., Woller, S. C., Bauer, K. A., Kasthuri, R., Cushman, M., Streiff, M., Lim, W., & Douketis, J. D. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1316-1 · Cited by 345
Daugherty, A., Tall, A. R., Daemen, M. J. A. P., Falk, E., Fisher, E. A., García-Cardeña, G., Lusis, A. J., Owens, A. P., Rosenfeld, M. E., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000062 · Cited by 316
Self-citation
Metadata
- Authors
- Bentzon, J. F., Daemen, M., Falk, E., Garcia-Garcia, H. M., Herrmann, J., Hoefer, I., Jukema, J. W., Krams, R., Kwak, B. R., Marx, N., Naruszewicz, M., Newby, A., Pasterkamp, G., Serruys, P. W. J. C., Waltenberger, J., Weber, C., Tokgözoglu, L., & Ylä-Herttuala, S.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2011
- Volume
- 106
- Issue
- 07
- Pages
- 1-19
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1832728002
- Cited by
- 143
- References
- 37
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.